Bolt Biotherapeutics, Inc. financial data

Symbol
BOLT on Nasdaq
Location
Redwood City, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 12 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 331% % -19%
Debt-to-equity 96% % 96%
Return On Equity -93% % -17%
Return On Assets -47% % 11%
Operating Margin -469% % 51%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,921,567 shares -95%
Common Stock, Shares, Outstanding 1,920,566 shares 0.19%
Entity Public Float $7,300,000 USD -67%
Common Stock, Value, Issued $0 USD
Weighted Average Number of Shares Outstanding, Basic 1,869,924 shares -2.1%
Weighted Average Number of Shares Outstanding, Diluted 1,869,924 shares -2.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $7,695,000 USD 0.06%
Research and Development Expense $28,533,000 USD -50%
General and Administrative Expense $13,795,000 USD -25%
Operating Income (Loss) $36,113,000 USD 51%
Nonoperating Income (Expense) $2,737,000 USD -72%
Net Income (Loss) Attributable to Parent $33,376,000 USD 47%
Earnings Per Share, Basic -17.85 USD/shares 46%
Earnings Per Share, Diluted -17.85 USD/shares 46%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $11,703,000 USD 62%
Cash, Cash Equivalents, and Short-term Investments $31,800,000 USD -55%
Assets, Current $30,260,000 USD -40%
Property, Plant and Equipment, Net $1,245,000 USD -60%
Operating Lease, Right-of-Use Asset $19,230,000 USD -12%
Other Assets, Noncurrent $138,000 USD 123%
Assets $56,748,000 USD -43%
Accounts Payable, Current $1,443,000 USD -4.2%
Employee-related Liabilities, Current $1,642,000 USD -61%
Liabilities, Current $8,435,000 USD -47%
Operating Lease, Liability, Noncurrent $20,132,000 USD -12%
Other Liabilities, Noncurrent $132,000 USD
Liabilities $30,243,000 USD -29%
Accumulated Other Comprehensive Income (Loss), Net of Tax $21,000 USD -122%
Retained Earnings (Accumulated Deficit) $460,779,000 USD -7.8%
Stockholders' Equity Attributable to Parent $26,505,000 USD -54%
Liabilities and Equity $56,748,000 USD -43%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $13,365,000 USD 20%
Net Cash Provided by (Used in) Financing Activities $0 USD
Net Cash Provided by (Used in) Investing Activities $14,551,000 USD 43%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 1,920,566 shares 0.19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,186,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13,441,000 USD 50%
Deferred Tax Assets, Valuation Allowance $103,593,000 USD 6.9%
Deferred Tax Assets, Gross $109,249,000 USD 5.7%
Operating Lease, Liability $22,958,000 USD -8.9%
Depreciation $1,300,000 USD -28%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $33,494,000 USD 47%
Lessee, Operating Lease, Liability, to be Paid $31,521,000 USD -14%
Property, Plant and Equipment, Gross $8,632,000 USD -17%
Operating Lease, Liability, Current $2,826,000 USD 26%
Lessee, Operating Lease, Liability, to be Paid, Year Two $5,584,000 USD 3.4%
Lessee, Operating Lease, Liability, to be Paid, Year One $5,399,000 USD 5.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.119 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $8,563,000 USD -25%
Lessee, Operating Lease, Liability, to be Paid, Year Three $5,775,000 USD 3.4%
Deferred Tax Assets, Operating Loss Carryforwards $66,024,000 USD 23%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $26,775,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid, Year Four $5,974,000 USD 3.4%
Operating Lease, Payments $1,242,000 USD 3.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $399,000 USD -13%
Deferred Tax Assets, Net of Valuation Allowance $5,656,000 USD -13%
Share-based Payment Arrangement, Expense $2,782,000 USD -62%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%